Woojin Han, PhD
- ASSISTANT PROFESSOR | Orthopedics, Orthopedic Research
Research Topics:
Biomechanics/Bioengineering, Biomedical Sciences, Muscle Cells, Orthopaedics, Regeneration, Stem Cells, Tissue EngineeringDr. Woojin Han is an Assistant Professor in the Leni and Peter W. May Department of Orthopaedics at the Icahn School of Medicine at Mount Sinai. Dr. Han leads the Laboratory for Cell-Instructive Biomaterials and Regenerative Engineering, which focuses on establishing translational technologies for musculoskeletal soft tissue regeneration by harnessing cell-matrix interactions. Dr. Han received his B.S. in Biomedical Engineering from the University of Rochester. He then completed his M.S.E and Ph.D. in Bioengineering at the University of Pennsylvania. His graduate work established how applied tissue-level mechanical strain is transferred to the underlying cells and regulates early cell responses in fiber-reinforced soft connective tissues. Using these findings as guiding criteria, Dr. Han and his team also developed a tissue-engineered platform that mimics the multi-scale structure-function relationships of the native fibrocartilaginous tissues, which enables a more controlled investigation of multi-scale biomechanics and mechanobiology. After completing his graduate studies, he pursued postdoctoral training at Georgia Institute of Technology, where he engineered fully synthetic, modular, and cell-instructive biomaterial for facilitating the transplantation and engraftment of muscle stem/satellite cells in the context of skeletal muscle trauma and diseases, such as Duchenne muscular dystrophy. He joined the faculty as an Assistant Professor of Orthopaedics at the Icahn School of Medicine at Mount Sinai in January 2021.
For more information, please see Han Lab and Orthopaedic Research Lab pages.
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Development Regeneration and Stem Cells [DRS]Education
BS, University of Rochester
MSE, University of Pennsylvania
PhD, University of Pennsylvania
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Han did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.